natgillin/translations-raw huggingface dataset:
Grade 3-5 reactions have been observed in up to 2.3% of patients treated with Avastin plus chemotherapy as compared with &lt; 1% with chemotherapy alone (NCI-CTCAE v.3).
Krvarenja stupnja 3-5 opažena su u do 2,3% bolesnika liječenih kombinacijom kemoterapije i lijeka Avastin u usporedbi s &lt; 1% u bolesnika liječenih samo kemoterapijom (NCI-CTCAE v.3).
Grade 4 ( &lt; 0.5x109/l)
Stupanj 4 ( &lt; 0,5x109/l)
Grade 4 (Platelets:  25,000/mm3)
Stupanj 4 (Broj trombocita: &lt; 25 000/mm3)
Grade 4 neutropenia ( &lt; 500 cells/mm3) occurred in 9% of patients treated with Abraxane.
Neutropenija 4. stupnja ( &lt; 500 stanica/mm3) javila se u 9% bolesnika liječenih lijekom Abraxane.
Grade 4(life-threatening) - &lt; 120 mmol/L despite appropriate fluid management
4. stupnja (opasno po život) - &lt; 120 mmol/L unatoč odgovarajućoj kontroli tekućina
Grade &gt; 3 haemorrhagic adverse reactions were reported in 3.1% of patients receiving axitinib (including cerebral haemorrhage, gastric haemorrhage, lower gastrointestinal haemorrhage and haemoptysis).
Epizode krvarenja stupnja &gt; 3 prijavljene su u 3,1% bolesnika koji su primali aksitinib (uključujući krvarenja u mozgu, želucu, donjem dijelu probavnog sustava i hemoptizu).
Grade &gt; 2 peripheral neuropathy
Periferna neuropatija stupnja ≥ 2
Grade ≥ 3 with AST or ALT &gt; 5 times ULN or total bilirubin &gt; 3 times ULN
≥3. stupanj s vrijednostima AST-a ili ALT-a &gt; 5 puta iznad GGN-a ili ako je ukupni bilirubin &gt; 3 puta iznad GGN-a
Grade &gt; 3 n (%)
Stupanj ≥ 3 n (%)
Gram negative anaerobes: S ≤ 1mg/L and R &gt; 1 mg/L
Gram-negativni anaerobi: S ≤1 mg/l i R &gt; 1 mg/l
Gram-positive isolates with an MIC &gt; 2 µg/ml are to be considered resistant.
Gram-pozitivni izolati kod kojih je minimalna inhibitorna koncentracija veća od 2 µg/ml trebaju se smatrati otpornima.
Grazoprevir was excreted into the milk of lactating rats with concentrations &lt; 1-fold of the maternal plasma concentrations.
Grazoprevir se izlučivao u mlijeko ženki štakora u laktaciji u koncentracijama &lt; 1 puta od koncentracija u majčinoj plazmi.
Greater patient satisfaction was correlated with improved range of motion (r=0.51, p &lt; 0.001).
Veće zadovoljstvo bolesnika koreliralo je s poboljšanim rasponom pokreta (r=0,51, p &lt; 0,001).
Greater than 10-fold resistance to tipranavir is uncommon ( &lt; 2.5% of tested isolates) in viruses obtained from highly treatment experienced patients who have received multiple peptidic protease inhibitors.
Desetorostruka ili veća otpornost na tipranavir je manje česta ( &lt; 2,5% testiranih izolata) u izolatima bolesnika s opsežnim prethodnim liječenjem koji su primali višestruke peptidne inhibitore proteaze.
Green &amp; Go
Zeleno i krenite
Growth disturbance (current height standard deviation score (SDS) &lt; -2.5 and parental adjusted height SDS &lt; -1) in short children/adolescents born small for gestational age (SGA), with a birth weight and/or length below -2 standard deviation (SD), who failed to show catch-up growth (height velocity (HV) SDS &lt; 0 during the last year) by 4 years of age or later.
Poremećaj rasta (skor standardne devijacije (SSD) trenutne visine &lt; -2,5 i SSD prilagođen visini roditelja &lt; -1) u niske djece/adolescenata koji su rođeni mali za gestacijsku dob s porođajnom težinom i/ili dužinom manjom od -2 standardne devijacije (SD), koja nisu uspjela nadoknaditi zaostajanje u rastu (SSD brzine rasta u visinu &lt; 0 u protekloj godini) do dobi od 4 godine ili kasnije.
Growth disturbance (current height standard deviation score (SDS) &lt; -2.5 and parental adjusted height SDS &lt; -1) in short children/adolescents born small for gestational age (SGA), with a birth weight and/or length below -2 standard deviation (SD), who failed to show catch-up growth (height velocity (HV) SDS &lt; 0 during the last year) by 4 years of age or later.
Poremećaj rasta (skor standardne devijacije (SSD) trenutne visine &lt; -2,5 i SSD prilagođen visini roditelja &lt; -1) u niske djece/adolescenata koji su rođeni mali za gestacijsku dob, s porođajnom težinom i/ili dužinom manjom od -2 standardne devijacije (SD), koja nisu uspjela nadoknaditi zaostajanje u rastu (SSD brzine rasta u visinu &lt; 0 u protekloj godini) do dobi od 4 godine ili kasnije.
Growth factor support was required infrequently ( &lt; 5%) and transfusion support was required in approximately 15% of patients (see section 4.2).
Potpora čimbenikom rasta nije bila često potrebna ( &lt; 5%), dok je potpora transfuzijom bila potrebna u približno 15% bolesnica (vidjeti dio 4.2).
Guanfacine showed significantly greater improvement compared to placebo on the change from baseline to final on treatment assessment in the ADHD Rating Scale (ADHD-RS-IV) score in both studies (placebo-adjusted reduction in LS mean range from 5.4 to 10.0, p &lt; 0.02).
Gvanfacin je pokazao značajno veće poboljšanje u usporedbi s placebom u promjeni rezultata na ljestvici procjene ADHD-a (ADHD-RS-IV) od početne do konačne procjene liječenja u oba ispitivanja (placebu prilagođeno smanjenje raspona srednjih vrijednosti dobivenih metodom najmanjih kvadrata (LS) od 5,4 do 10,0, p &lt; 0,02).
Guanfacine showed significantly greater improvement compared to placebo regardless of time (AM or PM) of administration (placebo-adjusted LS mean difference of -9.4 and -9.8 for AM and PM dosing, respectively, p &lt; 0.001).
Gvanfacin je pokazao značajno veće poboljšanje u usporedbi s placebom bez obzira na vrijeme primjene (ujutro ili navečer) (placebu prilagođena razlika srednjih vrijednosti dobivenih metodom najmanjih kvadrata od -9,4 za doziranje ujutro i -9,8 za doziranje navečer, p &lt; 0,001).
Haematocrit values &gt; 55% were reported in 1.3% of the subjects treated with dapagliflozin 10 mg versus 0.4% of
Vrijednosti hematokrita &gt; 55% prijavljene su u 1,3% ispitanika liječenih
Haematological improvement (major or minor) as determined by the IRC was achieved in 49 % of patients receiving azacitidine compared with 29 % of patients treated with combined CCR (p &lt; 0.0001).
Hematološko poboljšanje (veće ili manje) koje je ustanovio IRC postignuto je kod 49 % bolesnika koji su primali azacitidin u odnosu na 29 % bolesnika koji su liječeni kombinirano CCR-om (p &lt; 0,0001).
Haemodynamic effects: Minimal decreases in mean heart rate ( &lt; 2 beats per minute) and mean systolic blood pressure ( &lt; 3 mm Hg) were observed in patients treated with ranolazine either alone or in combination with other antianginal medicinal products in controlled studies.
Hemodinamički učinci: Minimalno smanjenje srednjeg broja srčanih otkucaja ( &lt; 2 otkucaja u minuti) i srednjeg sistoličkog krvnog tlaka ( &lt; 3 mm Hg) uočeno je u kontroliranim istraživanjima kod bolesnika liječenih samo ranolazinom ili u kombinaciji s drugim lijekovima protiv angine pektoris.
Haemoglobin &lt; 10 g/dl and either free bilirubin &gt; 1.5 ULN and haptoglobin &lt; 0.1 g/dl or reticulocytes &lt; 80,000/mm3
Hemoglobin &lt; 10 g/dl i slobodni bilirubin &gt; 1.5 GGN i haptoglobin &lt; 0.1 g/dl ili retikulociti &lt; 80.000/mm3
Haemoglobin &lt; 11 g/dl at baseline to &gt; 11 g/dl post baseline
Hemoglobin &lt; 11 g/dl za početne vrijednosti do &gt; 11 g/dl nakon početka
Haemoglobin concentrations were corrected to ≥ 10 g/dl in &gt; 98% (p &lt; 0.001) of paediatric patients administered darbepoetin alfa once weekly and 84% (p = 0.293) once every two weeks.
Koncentracije hemoglobina su ispravljene na ≥ 10 g/dl u &gt; 98% (p &lt; 0,001) pedijatrijskih bolesnika koji su primjenjivali darbepoetin alfa jednom tjedno te u 84% (p=0,293) bolesnika koji su lijek primjenjivali jednom u dva tjedna.
Haemoglobin increase &gt; 15 g/L (0.9 mmol/L) at Week 13/haemoglobin response-evaluable population
Povišenje hemoglobina &gt; 15 g/L (0,9 mmol/L) u 13. tjednu/populacija koja se može procijeniti na odgovor hemoglobina
Haemoglobin values of &lt; 10 g/dl were observed in 34% of patients who received INCIVO combination treatment and in 14% of patients who received peginterferon alfa and ribavirin.
Vrijednosti hemoglobina &lt; 10 g/dl bile su zabilježene u 34% bolesnika koji su primali terapiju kombiniranu s INCIVOM i 14% bolesnika koji su primali peginterferon alfa i ribavirin.
Haemoglobin values of &lt; 8.5 g/dl were observed in 8% of INCIVO combination treatment compared to 2% of patients receiving peginterferon alfa and ribavirin.
Vrijednosti hemoglobina &lt; 8,5 g/dl bile su zabilježene u 8% bolesnika koji su primali terapiju kombiniranu s INCIVOM u odnosu na 2% bolesnika koji su primali peginterferon alfa i ribavirin.
Haemophilus influenzae: S ≤ 0.5 mg/L and R &gt; 0.5 mg/L
Haemophilus influenzae: S ≤0,5 mg/l i R &gt; 0,5 mg/l
HAQ = Health Assessment Questionnaire; greater values indicate less disability. p = 0.030 and &lt; 0.001 for the 3 mg/kg and 6 mg/kg treatment groups respectively vs. placebo + MTX.
HAQ = upitnik za procjenu zdravlja (engl.Health Assesment Questionnaire); veće vrijednosti označavaju manji stupanj onesposobljenosti. p = 0,030 za skupinu koja je primala dozu od 3 mg/kg i p &lt; 0,001 za skupinu koja je primala dozu od 6 mg/kg u usporedbi s placebo + MTX.
Hazard Ratio (HR)1 (95% CI) 0.70 (0.59-0.83) p-value &lt; 0.0001
Omjer hazarda (HR)1 (95% CI) 0,70 (0,59-0,83) p-vrijednost &lt; 0,0001
Hazard ratio 0.46, CI95% 0.33; 0.64, p &lt; 0.001
Omjer hazarda 0,46, CI95% 0,33 ; 0,64, p &lt; 0,001
Hazard ratio 0.58, CI95% 0.43; 0.73, p &lt; 0.001
Omjer hazarda 0,58, CI95% 0,43 ; 0,73, p &lt; 0,001
HbA1c weight (%) (%) &lt; 7.0% (%) ≤6.5% (%) (mmol/L) (kg)
Promjena tjelesne težine
HBeAg negative (study 027): treatment with entecavir up to 96 weeks (n = 325) resulted in cumulative response rates of 94% for HBV DNA &lt; 300 copies/ml by PCR and 89% for ALT normalisation versus 77% for HBV DNA &lt; 300 copies/ml by PCR and 84% for ALT normalisation for lamivudine-treated patients (n = 313).
HBeAg negativni (ispitivanje 027): liječenje entekavirom u trajanju do 96 tjedana (n = 325) rezultiralo je kumulativnim stopama odgovora od 94% za HBV DNK &lt; 300 kopija/ml mjereno PCR-om i 89% za normalizaciju ALT-a, naspram kumulativne stope odgovora na liječenje lamivudinom (n = 313) od 77% za HBV DNK &lt; 300 kopija/ml mjereno PCR-om i 84% za normalizaciju ALT-a.
HBeAg positive (study 022): treatment with entecavir for up to 96 weeks (n = 354) resulted in cumulative response rates of 80% for HBV DNA &lt; 300 copies/ml by PCR, 87% for ALT normalisation, 31% for HBeAg seroconversion and 2% for HBsAg seroconversion (5% for HBsAg loss).
HBeAg pozitivni (ispitivanje 022): kumulativne stope odgovora na liječenje entekavirom u trajanju do 96 tjedana (n = 354) bile su 80% za HBV DNK &lt; 300 kopija/ml mjereno PCR-om, 87% za normalizaciju ALT, 31% za HBeAg serokonverziju i 2% za HBsAg serokonverziju (5% za nestanak HBsAg).
HBeAg positive (study 026): treatment with entecavir for up to 96 weeks (n = 141) resulted in cumulative response rates of 30% for HBV DNA &lt; 300 copies/ml by PCR, 85% for ALT normalisation and 17% for HBeAg seroconversion.
HBeAg pozitivni (ispitivanje 026): liječenje entekavirom u trajanju do 96 tjedana (n = 141) rezultiralo je kumulativnim stopama odgovora od 30% za HBV DNK &lt; 300 kopija/ml mjereno PCR-om, 85% za normalizaciju ALT-a i 17% za HBeAg serokonverziju.
HBeAg seroconversion was increased in patients with elevated ALT levels; 77 % (20/26) of patients with pre-treatment ALT &gt; 2 x ULN seroconverted.
Serokonverzija HBeAg bila je povećana u bolesnika s povišenim razinama ALT; do serokonverzije je došlo u 77 % (20/26) bolesnika koji su prije liječenja imali razine ALT &gt; 2 x veće od gornje granice normale.
HBV DNA &lt; 50 IU/mL and
HBV DNK &lt; 50 IU/ml i
HBV DNA &lt; 50 IU/mLa
HBV DNK &lt; 50 IU/mla
HBV DNA undetectable ( &lt; 300 copies/ml by PCR)c
HBV DNK nemjerljiva ( &lt; 300 kopija/ml pomoću PCR)c
HCV RNA &lt; 25 IU/ml at End of Treatment
Početni HCV RNK ≥ 800 000 IU/ml
HCV RNA &lt; 6 million IU/mL
HCV RNK &lt; 6 milijuna IU/ml
HCV RNA &gt; 1,000 IU/ml at week 12 of treatmenta
HCV RNK &gt; 1000 IU/ml nakon 12 tjedana liječenjaa
HCV RNA &gt; 1,000 IU/ml at week 4 of treatmenta
HCV RNK &gt; 1000 IU/ml nakon 4 tjedna liječenjaa
HCV RNA ≥ 6 million IU/mL
HCV RNK &gt; 6 milijuna IU/ml
Heart rate &lt; 45 bpm.
Srčana frekvencija &lt; 45 otkucaja u minuti.
Heavy metal chelation therapy should be considered if plasma zinc levels are markedly elevated ( &gt; 10 mg/l).
Kelirajuću terapiju teškim metalima treba razmotriti ako je razina cinka u plazmi značajno povišena ( &gt; 10 mg/l).
Hemodialysis does not result in meaningful removal of tedizolid from systemic circulation, as assessed in subjects with end-stage renal disease (eGFR &lt; 15 mL/min).
Hemodijaliza ne rezultira značajnim uklanjanjem tedizolida iz sistemske cirkulacije, kao što je procijenjeno u ispitanika u završnoj fazi bubrežne bolesti (eGFR &lt; 15 ml/min).
Hence the risk of haematological toxicity may be increased when Zevalin is administered shortly ( &lt; 4 months) after fludarabine-containing regimens (see also section 4.4).
Stoga bi rizik od hematološke toksičnosti mogao biti veći kad se Zevalin primjenjuje neposredno ( &lt; 4 mjeseca) nakon terapijskog režima koji sadrži fludarabin (vidjeti također dio 4.4).
Hepatic failure ( &lt; 1%)
zatajenje jetre ( &lt; 1%)
Hepatic failure and acute hepatitis ( &lt; 1%; see section 4.8, Description of selected adverse reactions) have been reported in patients treated with lenvatinib.
U bolesnika liječenih lenvatinibom zabilježeni su zatajenje jetre i akutni hepatitis ( &lt; 1%; vidjeti dio 4.8, Opis odabranih nuspojava).
Hepatobiliary disorders: Cholestasis, Hepatitis (incl. hepatocellular injury) (In the pooled phase III trials, these events were rare (≥ 1/10,000 to &lt; 1/1,000)).
Poremećaji jetre i žuči: kolestaza, hepatitis (uključujući hepatocelularno oštećenje) (u objedinjenim ispitivanjima faze III, ti su događaji bili rijetki (≥ 1/10,000 i &lt; 1/1,000)).
Herbal Preparation St. John’s wort Herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of ritonavir (see section 4.5).
Biljni pripravci Gospina trava Biljni pripravci koji sadržavaju gospinu travu (Hypericum perforatum), zbog rizika od smanjenih koncentracija u plazmi i slabijih kliničkih učinaka ritonavira (vidjeti dio 4.5).
Herbal products St. John’s wort Herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of lopinavir and ritonavir (see section 4.5).
Biljni lijekovi Gospina trava Biljni pripravci koji sadrže gospinu travu (Hypericum perforatum) ne smiju se uzimati za vrijeme primjene lopinavira i ritonavira zbog rizika od smanjenja koncentracije lopinavira i ritonavira u plazmi, a time i slabljenja njihovih kliničkih učinaka (vidjeti dio 4.5).
Herpes zoster (inc disseminated &amp; ophthalmic), Pneumonia*, Herpes simplex*, Fungal infection*
Herpes zoster (uključujući diseminirani i oftalmički), pneumonija*, herpes simpleks*, gljivična infekcija
High anti-pegloticase antibody titres were associated with a failure to maintain normalisation of uric acid ( &lt; 6 mg/dl).
Visoki titri protutijela na peglotikazu bili su povezani sa neuspjehom održavanja normalizacije razine mokraćne kiseline ( &lt; 6 mg/dl).
High baseline ALT levels (≥ 2 x ULN) and Knodell Histology Activity Index (HAI) scores (≥ 10) and low HBV DNA ( &lt; 7.6 log10 copies/ml) were associated with greater histological improvement.
Visoke početne razine ALT-a (≥ 2 x GGN) i visok Knodellov indeks histološke aktivnosti (HAI) (≥ 10) te niska razina HBV DNK ( &lt; 7,6 log10 kopija/ml) bili su povezani s većim histološkim poboljšanjem.
High baseline Knodell necroinflammatory scores ( &gt; 10) were associated with greater histological improvement in nucleoside-naive patients.
Visoki početni Knodellov indeks nekroze i upale ( &gt; 10) bio je povezan s većim histološkim poboljšanjem kod bolesnika prethodno neliječenih analozima nukleozida.
High doses of ketoconazole ( &gt; 200 mg/day) are not recommended.
&gt; 20 puta iznad gornje granice normale
High doses of ketoconazole and itraconazole ( &gt; 200 mg/day) are not recommended.
/ritonavirom; ne preporučuju se visoke doze ketokonazola i itrakonazola ( &gt; 200 mg na dan).
High tumour burden is defined as having at least one of the following: bulky tumour mass ( &gt; 7 cm), involvement of three or more nodal sites (each &gt; 3 cm), systemic symptoms (weight loss &gt; 10 %, pyrexia &gt; 38°C for more than 8 days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia.
Veliko tumorsko opterećenje definira se kao postojanje najmanje jednog od sljedećih nalaza: velika tumorska masa ( &gt; 7 cm), zahvaćenost triju ili više limfnih čvorova (svaki &gt; 3 cm), sustavni simptomi (gubitak tjelesne težine &gt; 10%, pireksija &gt; 38°C dulje od 8 dana ili noćno znojenje), splenomegalija koja prelazi granicu pupka, opstrukcija važnih organa ili kompresijski sindrom, zahvaćenost orbite ili epiduralnih struktura, serozni izljev ili leukemija.
Higher frequencies in the Cotellic plus vemurafenib arm were observed for cerebral haemorrhage (1% vs 0%), gastrointestinal tract haemorrhage (4% vs 1%), reproductive system haemorrhage (2% vs &lt; 1%) and haematuria (3% vs 1%).
Veća učestalost pojavljivanja u skupini liječenoj lijekom Cotellic plus vemurafenibom primijećena je za cerebralno krvarenje (1% naspram 0%), gastrointestinalno krvarenje (4% naspram 1%), krvarenje u reproduktivnom sustavu (2% naspram &lt; 1%) i hematuriju (3% naspram 1%).
Higher mean patient global satisfaction scores, indicating a higher level of overall satisfaction, were seen in the ingenol mebutate groups compared to the vehicle groups (p &lt; 0.001) as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).
Viša aritmetička sredina rezultata općeg zadovoljstva bolesnika, koja upućuje na višu razinu ukupnog zadovoljstva, uočena je u skupinama koje su primale ingenol mebutat u usporedbi sa skupinama koje su primale podlogu (p &lt; 0,001), određena pomoću Upitnika o zadovoljstvu liječenjem (TSQM).
HIV RNA &lt; 400 copies/ml
HIV RNA &lt; 400 kopija/ml
HIV RNA &lt; 400 copies/ml (ITT)*
HIV RNA &lt; 400 kopija/ml (ITT)
HIV RNA &lt; 400 copies/ml*
HIV RNA &lt; 400 kopija/ml
HIV RNA &lt; 400 copies/ml, treatment response, %
HIV RNA &lt; 400 kopija/ml, terapijski odgovor (%)
HIV RNA &lt; 50 copies/ml
HIV RNA &lt; 50 kopija/ml
HIV RNA &lt; 50 copies/ml (ITT)*
HIV RNA &lt; 50 kopija/ml (ITT)
HIV RNA &lt; 50 copies/ml*†
HIV RNA &lt; 50 kopija/ml
HIV RNA &lt; 50 copies/ml, treatment response, %
HIV RNA &lt; 50 kopija/ml, terapijski odgovor (%)
HIV RNA &lt; 400 copies/ml, % a
HIV RNK &lt; 400 kopija/ml, % a
HIV RNA &lt; 400 copies/ml, %a
HIV RNK &lt; 400 kopija/ml, %a
HIV RNA &lt; 50 copies/ml by select baseline PI substitutions,c % (responder/evaluabled)
HIV RNK &lt; 50 kopija/ml prema početnim odabranim supstitucijama za rezistenciju na
HIV RNA &lt; 50 copies/ml by select baseline PI substitutions,c % (responder/evaluabled)
HIV RNK &lt; 50 kopija/ml prema početnim odabranim supstitucijama za rezistenciju na inhibitor proteaze,c % (bolesnici s odgovorom/bolesnici koje se moglo procijenitid)
HIV RNA &lt; 50 copies/ml by select baseline PI substitutions,f, g % (responder/evaluable)
HIV RNK &lt; 50 kopija/ml prema odabranim supstitucijama za rezistenciju na inhibitor proteaze na početku ispitivanja,f, g % bolesnici s odgovorom/bolesnici koji su se mogli procijeniti)
HIV RNA &lt; 50 copies/ml, %
HIV RNK &lt; 50 kopija/ml,
HIV RNA &lt; 50 copies/ml, % a
HIV RNK &lt; 50 kopija/ml, % a
HIV RNA &lt; 50 copies/ml, % by Baseline Characteristicd
HIV RNK &lt; 50 kopija/ml, % prema početnim značajkamad
HIV RNA &lt; 50 copies/ml, %a
HIV RNK &lt; 50 kopija/ ml, %a
HIV RNA &lt; 50 copies/ml, %f (responder/evaluable)
HIV RNK &lt; 50 kopija/ml, %f (bolesnici s odgovorom/bolesnici koji su se mogli procijeniti)
HIV RNA &gt; 1 log below Baseline**
HIV RNK ≥1 log manje od početnih vrijednosti
HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated patients in Africa and Asia were susceptible to abacavir (IC50 fold changes &lt; 2.5), and lamivudine (IC50 fold changes &lt; 3.0), except for two CRF02_AG isolates with fold changes of 2.9 and 3.4 for abacavir.
Izolati HIV-1 (CRF01_AE, n=12; CRF02_AG, n=12; i podvrsta C ili CRF_AC, n=13) prikupljeni u 37 neliječenih bolesnika u Africi i Aziji bili su osjetljivi na abakavir (promjena IC50 &lt; 2,5 puta) i lamivudin (promjena IC50 &lt; 3,0 puta), osim dvaju izolata CRF02_AG kod kojih se vrijednost za abakavir promijenila 2,9 i 3,4 puta.
HIV-1 isolates (CRF01_AE, n=12; CRF02_AG, n=12; and Subtype C or CRF_AC, n=13) from 37 untreated patients in Africa and Asia were susceptible to abacavir (IC50 fold changes &lt; 2.5), and lamivudine (IC50 fold changes &lt; 3.0), except for two CRF02_AG isolates with fold-changes of 2.9 and for abacavir.
HIV-1 izolati (CRF01_AE, n=12; CRF02_AG, n=12; i podtip C ili CRF_AC, n=13) od 37 neliječenih bolesnika iz Afrike i Azije bili su osjetljivi na abakavir (IC50 promjena &lt; 2,5 puta), i lamivudin (IC50 promjena &lt; 3,0 puta), osim u slučaju dva CRF02_AG izolata u kojih je promjena za abakavir bila 2,9 i 3,4 puta.
HIV-1 RNA &lt; 20 copies/mL
HIV-1 RNA &lt; 20 kopija/ml
HIV-1 RNA &lt; 400 copies/ml
HIV-1 RNK &lt; 400 kopija/ml
HIV-1 RNA &lt; 50 copies/ml
HIV-1 RNK &lt; 50 kopija/ml
HIV-1 RNA &lt; 50 copies/mL
HIV-1 RNK &lt; 50 kopija/ml na prvotnom režimu liječenja
HIV-1 RNA &lt; 50 copies/mla
HIV-1 RNK &lt; 50 kopija/mla
HIV-1 RNA &lt; 50 copies/mL
HIV-1 RNA 50 kopija/ml
HIV-1 RNA &lt; 50 copies/mL
HIV-1 RNK &lt; 50 kopija/ml
HIV-1 RNA &lt; 50 copies/mL by baseline covariates
HIV-1 RNK &lt; 50 kopija/ml prema početnim kovarijantama
HIV-1 RNA &lt; 50 copies/mL for those on ABC/3TC
HIV-1 RNK &lt; 50 kopija/ml u bolesnika koji primaju ABC/3TC
HIV-1 RNA &lt; 50copies/mL for those on ABC/3TC
HIV-1 RNK &lt; 50 kopija/ml u bolesnika koji primaju ABC/3TC
HIV-1 RNA &gt; 100,000 copies/ml
HIV-1 RNK &gt; 100 000 kopija/ml 8
HIV-1 RNA &gt; 100,000 copies/ml 8 %
HIV-1 RNK &gt; 100 000 kopija/ml 8
HIV-1: In adolescents aged 12 to &lt; 18 years and weighing ≥ 35 kg, the recommended dose of Viread is 245 mg (one tablet) once daily taken orally with food (see sections 4.8 and 5.1).
HIV-1: U adolescenata u dobi od 12 do &lt; 18 godina i tjelesne težine ≥ 35 kg, preporučena doza Vireada je 245 mg (jedna tableta) jedanput na dan koja se uzima peroralno s hranom (vidjeti dijelove 4.8 i 5.1).
HIV-1: In study GS-US-104-0321, 87 HIV-1 infected treatment-experienced patients 12 to &lt; 18 years of age were treated with tenofovir disoproxil fumarate (n = 45) or placebo (n = 42) in combination with an optimised background regimen (OBR) for 48 weeks.
HIV-1: U ispitivanju GS-US-104-0321, 87 prethodno liječenih pacijenata zaraženih virusom HIV-1, u dobi od 12 do 18 godina starosti, primali su tenofovirdizoproksilfumarat (n = 45) ili placebo (n = 42) u kombinaciji s optimiziranim pozadinskim režimom (OBR) tijekom 48 tjedana.
HIV-1: Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1 infected adolescent patients (aged 12 to &lt; 18 years) with body weight ≥ 35 kg.
HIV-1: Farmakokinetika tenofovira u stanju dinamičke ravnoteže procijenjena je u 8 adolescentnih pacijenata zaraženih HIVom (u dobi od 12 do 18) s tjelesnom težinom ≥ 35 kg.
HIV-RNA &gt; 100,000 copies/ml
HIV-RNK &gt; 100 000 kopija/ml
However a higher variability was observed in children &lt; 9 kg leading to 60% of children achieving the therapeutic window (900 - 1500 µmol/L.minute).
No u djece &lt; 9 kg postignuta je veća varijabilnost koja je dovela do toga da 60% djece postigne terapijski okvir (900-1500 μmol/l.minuta).
However a higher variability was observed in children &lt; 9 kg leading to 60% of children achieving the therapeutic window (900-1500 µmol/L.minute).
No u djece &lt; 9 kg postignuta je veća varijabilnost koja je dovela do toga da 60% djece postigne terapijski okvir (900-1500 µmol/l.minuta).